Novo Nordisk

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Beta Bionics, a medical technology company, developed the iLet Bionic Pancreas for people with type 1 diabetes. It is an automated system that can deliver insulin in one or two hormone modes, automatically calculating and administering all insulin doses needed.&nbsp; The FDA-approved iLet Bionic Pancreas eliminates traditional setup, carbohydrate counting, correction, and bolus calculation.&nbsp;The system is compatible with two continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM. It is a pocket-sized, wearable medical device that uses ML algorithms to control blood sugar levels in people with diabetes. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas.Key customers and partnershipsThe company has collaborated with pharmaceutical companies to improve its lead technology: <a href="https://www.betabionics.com/zealand-and-beta-bionics-to-collaborate-on-the-development-of-a-first-in-class-dual-hormonal-bionic-pancreas-system-for-treatment-of-people-with-type-1-diabetes/">Zealand Pharma</a> (June 2016) to develop a new dual-hormonal artificial pancreas system for the treatment of diabetes and <a href="https://www.betabionics.com/beta-bionics-and-convatec-announce-partnership-to-bring-unomedical-infusion-set-portfolio-to-the-ilet-bionic-pancreas-system/">ConvaTec</a> (July 2019) to manufacture infusion sets for use with Beta Bionics' iLet Bionic Pancreas System, which autonomously controls blood sugar levels in people with diabetes.&nbsp;Funding and financialsIn August 2023, the company raised USD 100 million in <a href="https://sp-edge.com/updates/21628">Series D funding</a> co-led by Sands Capital and Omega Funds to expand access to the iLet Bionic Pancreas across the US and further develop and test the bi-hormonal bionic pancreas.

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries.&nbsp;As of March 2022, the company had acquired two companies: 1) <a href="https://sp-edge.com/updates/8154">xbird </a>, a German AI-backed medical company, and 2) French diabetes care platform <a href="https://sp-edge.com/updates/9200?industryIds=22">DIABNEXT </a>as part of its planned global expansion drive. The integration of xbird’s Just In Time Adaptive Intervention technology will enhance Glooko’s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which will allow the company to scale its operations into more regions and expand its remote patient monitoring services.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/25233">January 2024</a>, the company partnered with Better Therapeutics to integrat Better Therapeutics' recently launched AspyreRx , a digital behavioral treatment for type 2 diabetes (T2D), into Glooko's platform.Funding and financials&nbsp;In March 2021, the company concluded a Series D round that brought its total funding up to USD 101 million to enter new geographical locations and expand its clinical product offerings to cover other chronic diseases.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Ventus Therapeutics develops novel therapeutics for various therapeutic areas including autoimmune diseases, neurological disorders, and inflammation. The company&rsquo;s approach is based on exploring unknown or poorly understood binding pockets on protein surfaces and screening billions of compounds to identify small molecules suitable to match the pockets. To do this, it leverages its AI-powered computational drug discovery platform, ReSOLVE, which combines structural biology, protein science, and chemistry capabilities.
 
 
 As of March 2024,Ventus had three drug candidates in its pipeline, namely 1) VENT-03, a cGAS inhibitor; 2) VENT-02, a brain-penetrant NLRP3 inhibitor; and 3) VENT-01, a systemic NLRP3 inhibitor. The company has advanced VENT-02 and VENT-03 into Phase I clinical trials.&nbsp;
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://mila.quebec/en/ventus-mila/">
 November 2022
 </a>
 , the company partnered with Mila, an AI research institute, to integrate advanced machine-learning capabilities into the ReSOLVE platform. Further, in 
 <a href="https://www.ventustx.com/ventus-therapeutics-enters-exclusive-development-and-license-agreement-with-novo-nordisk-for-nlrp3-inhibitor-program/">
 September 2022
 </a>
 , the company partnered with Novo Nordisk to advance its NLRP3 inhibitor program, targeting a range of liver, kidney, and cardiometabolic diseases.
 
 
 Funding and financials
 
 
 In February 2022, Ventus raised USD 140 million in a 
 <a href="https://sp-edge.com/updates/8386">
 Series C 
 </a>
 funding round co-led by Softbank Vision Fund 2 and RA Capital Management. GV (formerly Google Ventures) also participated in the round. The proceeds were earmarked for developing the company&rsquo;s computational platform, advancing its drug pipeline, and establishing proprietary virtual libraries. As of August 2022, Ventus had raised an aggregate of USD 300 million in private funding. 
 
</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko&rsquo;s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices. 
 
 
 The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries. As of March 2022, the company had acquired two companies: 1) 
 <a href="https://sp-edge.com/updates/8154">
 xbird
 </a>
 , a German AI-backed medical company, and 2) French diabetes care platform 
 <a href="https://sp-edge.com/updates/9200?industryIds=22">
 DIABNEXT
 </a>
 as part of its planned global expansion drive. The integration of xbird&rsquo;s Just In Time Adaptive Intervention technology will enhance Glooko&rsquo;s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which allow the company to scale its operations into more regions and expand its remote patient monitoring services.
 
 
 Founded in 2010, Glooko is headquartered in both California and Sweden. In March 2021, the company concluded a Series D round that brought its total funding up to USD 101 million to enter new geographical locations and expand its clinical product offerings to cover other chronic diseases. 
 
</div>

Reinventing gene therapies with next-generation technologies

Human Gene Editing

<div>
 
 ElevateBio develops novel cell, gene and regenerative therapies by leveraging technologies such as gene editing, Induced Pluripotent Stem Cells (iPSCs), and cell, protein, and vector engineering. It develops its own therapies whilst also offering its technologies to other biotech and pharmaceutical companies to accelerate the drug development process. It also provides manufacturing support to other cell and gene therapy companies through its centralized R&amp;D and manufacturing company BaseCamp, which offers process development services, current Good Manufacturing Practices (cGMP) grade manufacturing of cell and viral vectors such as adeno-associated virus (AAV), and quality assurance.&nbsp;
 
 
 The company&rsquo;s focus lies on spinning out separate entities for specific therapeutic areas or indications, and has thus far disclosed three such spin-outs: 1) AlloVir (in partnership with Baylor College of Medicine) to tackle infectious diseases primarily targeting 12 viruses; 2) HighPassBio (joint venture with gene editing company Fred Hutchinson to prevent relapsing leukemia; 3) Life Edit Therapeutics (wholly owned gene editing company) to target genetic diseases.&nbsp;
 
 
 Life Edit Therapeutics, which was acquired by ElevateBio in 
 <a href="https://www.biospace.com/article/elevatebio-acquires-life-edit-therapeutics-and-its-next-generation-gene-editing-platform/">
 October 2021
 </a>
 , maintains a large database of ribonucleic acid (RNA)-guided nucleases (RGNs), base editors, and Protospacer Adjacent Motifs (PAMs)&mdash;short sequences that support an enzyme to edit a gene&mdash;for greater specificity and broader genome coverage. Life Edit&rsquo;s gene editing platform enables both in vivo (gene editing done inside the body) delivery and ex vivo (gene editing done in a specialized laboratory and returned to the body) engineering.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has entered into a number of partnerships to offer its manufacturing capabilities and BaseCamp services, which include a 10-year partnership with the 
 <a href="https://www.elevate.bio/blogs/massachusetts-general-hospital-and-elevatebio-announce-a-10-year-alliance-agreement-to-utilize-elevatebio-basecamp-to-manufacture-innovative-cell-and-gene-therapies">
 Massachusetts General Hospital
 </a>
 (July 2019) and a five-year collaboration with the 
 <a href="https://www.elevate.bio/blogs/boston-childrens-hospital-and-elevatebio-announce-five-year-cell-and-gene-therapy-collaboration">
 Boston Children&rsquo;s Hospital
 </a>
 (June 2021) and 
 <a href="https://www.globenewswire.com/news-release/2020/11/10/2123755/0/en/TCR-Therapeutics-Announces-Partnership-with-ElevateBio-to-Expand-TC-210-Manufacturing-Capacity.html">
 TCR2 Therapeutics
 </a>
 (November 2020).
 
 
 Most recently, ElevateBio partnered with 
 <a href="https://sp-edge.com/companies/243071">
 Xcell Biosciences
 </a>
 in January 2024 to develop cell and gene therapies. Through the partnership, ElevateBio became the first member of Xcellbio&rsquo;s beta program for its new AVATAR Foundry device. In addition, Michael Paglia, Chief Technology Officer at ElevateBio&rsquo;s BaseCamp, joined Xcellbio&rsquo;s Scientific Advisory Board. Further, ElevateBio BaseCamp scientists gained access to Xcellbio&rsquo;s AVATAR incubator system for cell therapy research and development as well as two new platforms: the AVATAR Ai system for measuring the potency of cell therapies and the AVATAR Foundry system for cGMP cell therapy manufacturing.
 
 
 ElevateBio also partnered with 
 <a href="https://sp-edge.com/companies/898118">
 Kyverna Therapeutics
 </a>
 in September 2023 to advance a CAR-T platform. Through the partnership, the companies agreed to expand process development and production of Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies. 
 
 
 In February 2023, ElevateBio&rsquo;s subsidiary, Life Edit Therapeutics, partnered with 
 <a href="https://sp-edge.com/updates/16598">
 Moderna Therapeutics
 </a>
 to develop novel therapeutics for genetic and other diseases. Soon after, Life Edit entered a partnership with 
 <a href="https://sp-edge.com/updates/18837">
 Novo Nordisk
 </a>
 in May 2023 to develop novel base-editing treatments for a number of diseases.
 
 
 Funding and financials
 
 
 In a 
 <a href="https://sp-edge.com/updates/18837">
 Series D
 </a>
 funding round in May 2023 led by the AyurMaya Capital Management Fund, ElevateBio raised USD 401 million to fuel the development of its gene-editing platforms and to support its expansion plans. This round followed the company&rsquo;s substantial USD 525 million 
 <a href="https://techcrunch.com/2021/03/15/elevatebio-raises-525m-to-advance-its-cell-and-gene-therapy-technologies/">
 Series C
 </a>
 round in March 2021, bringing the total funds raised to date to USD 1.2 billion.
 
</div>

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

<div>
 
 Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development and commercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic.
 
</div>

Preserving aquatic life for future generations

Sustainable Aquaculture

<div>
 
 Sundew is a biotechnology company that provides biological services for the treatment of aquatic pests and diseases. The company was founded in 2018 and is headquartered in Copenhagen,
 
</div>

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

Aspect Biosystems is a biotechnology company developing bioprinted tissue therapeutics to transform how we treat disease. By combining its proprietary microfluidic 3D bioprinting technology, therapeutic cells, and materials science, Aspect is creating a pipeline of allogeneic cell-based tissue therapeutics to replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine.

The Sabi is a community-driven holistic beauty brand that empowers women from conception to postpartum, menopause, and everyday hormonal woes.

Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

Glooko develops a remote patient-monitoring platform to identify at-risk patients with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to allow data capture and provide reports and analytics that aim to drive behavior change and outcomes.

Sundew is a biotechnology company that provides biological services for the treatment of aquatic pests and diseases. The company was founded in 2018 and is headquartered in Copenhagen,

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.  The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.  The Companyâ€™s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy.  The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.  The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

<div> Novo Nordisk is a pharmaceutical manufacturing company that specializes in Insulin, obesity, rare diseases, and diabetes. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. </div>

Novo Nordisk

Featured Industries

Recent Updates

Cellarity and Novo Nordisk collaborate for cardiometabolic disease treatments

Novo Nordisk launches AI research facility in London

Genevant Sciences and Novo Nordisk partners to develop treatment for hemophilia A

Valo Health and Novo Nordisk collaborate to research cardiometabolic treatments

ElevateBio raises USD 401 million in Series D; LifeEdit partners with Novo Nordisk

Dewpoint Therapeutics partners with Novo Nordisk to treat insulin resistance and diabetic complications

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless